PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
E B Bröcker Selected Research
Bullous Pemphigoid (Pemphigoid)
09/2005
Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
12/2001
Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230.
04/2001
The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone.
11/2000
Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen.
11/2000
Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
11/2000
Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes.
04/2000
Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
04/2000
IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
02/2000
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
Articles by Research Topic
Disease
9
Melanoma (Melanoma, Malignant)
04/2008 - 10/2000
9
Bullous Pemphigoid (Pemphigoid)
09/2005 - 02/2000
2
Neoplasm Metastasis (Metastasis)
02/2004 - 01/2001
2
Skin Diseases
12/2001 - 05/2000
2
Benign Mucous Membrane Pemphigoid (Cicatricial Pemphigoid)
12/2001 - 11/2001
2
Neoplasms (Cancer)
08/2001 - 02/2001
1
B-Cell Lymphoma (Lymphoma, B Cell)
05/2007
1
Skin Neoplasms (Skin Cancer)
07/2006
1
Cysts
01/2005
1
Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/2005
1
Hemangiosarcoma (Angiosarcoma)
10/2001
1
Eczema
10/2001
1
Keratoacanthoma
08/2001
1
Pancytopenia
08/2001
1
Anaphylaxis (Anaphylactic Shock)
08/2001
1
Hypersensitivity (Allergy)
04/2001
1
Anoxia (Hypoxia)
03/2001
1
Blister (Bulla)
01/2001
1
Contact Dermatitis (Eczema, Contact)
10/2000
1
Epidermolysis Bullosa Simplex (Epidermolysis Bullosa Herpetiformis Dowling Meara)
02/2000
Drug/Important Bio-Agent (IBA)
6
Autoantibodies
IBA
12/2001 - 02/2000
4
Immunoglobulin G (IgG)
IBA
11/2001 - 04/2000
3
Immunoglobulin A (IgA)
IBA
11/2001 - 05/2000
3
Immunoglobulin E (IgE)
IBA
08/2001 - 04/2000
3
Interleukin-8 (Interleukin 8)
IBA
04/2001 - 11/2000
2
Interleukin-2 (IL2)
IBA
01/2002 - 10/2000
2
Epitopes
IBA
11/2001 - 04/2000
2
Antibodies
IBA
04/2001 - 01/2001
1
temozolomide (Temodar)
FDA Link
04/2008
1
peginterferon alfa-2b (Pegintron)
FDA Link
04/2008
1
rituximab (Mabthera)
FDA Link
05/2007
1
Cyclin D1
IBA
07/2006
1
Tryptophan (L-Tryptophan)
FDA Link
09/2005
1
Isotretinoin (Accutane)
FDA Link
Generic
01/2005
1
viscum album peptide (Iscador)
IBA
02/2004
1
Enzymes
IBA
09/2002
1
Integrin beta4
IBA
12/2001
1
Autoantigens
IBA
12/2001
1
Doxorubicin (Adriamycin)
FDA Link
Generic
10/2001
1
Cadherins (E-Cadherin)
IBA
10/2001
1
T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)
IBA
08/2001
1
Methotrexate (Mexate)
FDA Link
Generic
08/2001
1
Interleukin-4 (Interleukin 4)
IBA
08/2001
1
Dinitrochlorobenzene (DNCB)
IBA
06/2001
1
Dacarbazine (DIC)
FDA Link
Generic
06/2001
1
Antigens
IBA
04/2001
1
Dapsone
FDA Link
04/2001
1
Phosphotransferases (Kinase)
IBA
03/2001
1
Protein Kinases (Protein Kinase)
IBA
03/2001
1
Lymphotoxin-alpha (Lymphotoxin)
IBA
02/2001
1
Paraffin
IBA
01/2001
1
Monophenol Monooxygenase (Tyrosinase)
IBA
01/2001
1
Desmogleins
IBA
01/2001
1
Interleukin-6 (Interleukin 6)
IBA
11/2000
1
Collagen Type VII
IBA
11/2000
1
kalinin
IBA
11/2000
1
Messenger RNA (mRNA)
IBA
11/2000
1
fotemustine (Muphoran)
IBA
10/2000
1
Nerve Growth Factor (NGF)
IBA
10/2000
1
Immunoglobulins (Immunoglobulin)
IBA
04/2000
1
Plectin
IBA
02/2000
Therapy/Procedure
1
Aftercare (After-Treatment)
08/2001
1
Immunotherapy
01/2001